Rituxan (rituximab) - Roche
Soliris (eculizumab) - AstraZeneca
Unsuspected Recurrent FSGS and Complement Dysregulation in a Kidney Transplant Recipient with ADPKD (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1164; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Eculizumab reduced C5b-9 but proteinuria persisted (peak 9.57 g/day; Cr 194 µmol/L). Rituximab plus double-filtration plasmapheresis partially reduced proteinuria...Superimposed complement dysregulation likely accelerated allograft damage. Comprehensive serologic and pathologic workup is essential to identify occult primary FSGS in ADPKD recipients." 
Clinical • Autosomal Dominant Polycystic Kidney Disease • Chronic Kidney Disease • Fibrosis • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Hematological Disorders • Immunology • Nephrology • Polycystic Kidney Disease • Thrombocytopenia • Transplantation • LAMA5
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4556960
 
Xiaokai Yang; Lilin Liu; Yi Fang; Min Gu; Chunsun Dai; Hongdi Cao
 
Oct 2, 2026
 
Prev Next